Evidence map›Paper›PMID 35901838›Full record

ArticleNeuro-oncology2023

Cross-platform analysis reveals cellular and molecular landscape of glioblastoma invasion.

Ann T Chen, Yang Xiao, Xiangjun Tang, Mehdi Baqri, Xingchun Gao, Melanie Reschke, Wendy C Sheu, Gretchen Long, Yu Zhou, Gang Deng and 11 more

Open access · greenAbstract read
In one paragraph

Article in Neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 1 country.

Ann T ChenDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.
Yang XiaoDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.
Xiangjun TangDepartment of Neurosurgery, Yale University, New Haven, CT, USA.
Mehdi BaqriDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.
Xingchun GaoDepartment of Neurosurgery, Yale University, New Haven, CT, USA.
Melanie ReschkeDepartment of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT, USA.
Wendy C SheuDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.
Gretchen LongDepartment of Neurosurgery, Yale University, New Haven, CT, USA.
Yu ZhouDepartment of Neurosurgery, Yale University, New Haven, CT, USA.
Gang DengDepartment of Neurosurgery, Yale University, New Haven, CT, USA.
Shenqi ZhangDepartment of Neurosurgery, Yale University, New Haven, CT, USA.
Yanxiang DengDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.
Zhiliang BaiDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.
Dongjoo KimDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.
Anita HuttnerDepartment of Pathology, Yale University, New Haven, CT, USA.
Russell KunesDepartment of Statistics, Columbia University, New York, NY, USA.
Murat GünelDepartment of Neurosurgery, Yale University, New Haven, CT, USA.
Jennifer MoliternoDepartment of Neurosurgery, Yale University, New Haven, CT, USA.
W Mark SaltzmanDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.
Rong FanDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.
Jiangbing ZhouDepartment of Biomedical Engineering, Yale University, New Haven, CT, USA.ORCID 0000-0002-1201-5360
Yale University · USColumbia University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Ex vivo analysis of human brain tumor cells in a microvascular niche modelR01CA245313 · NCI · YALE UNIVERSITY · PI FAN, RONG, ZHOU, JIANGBING · 2020 to 2024
$2.6M
Systemic gene therapy for glioblastomaR01NS095817 · NINDS · YALE UNIVERSITY · PI ZHOU, JIANGBING · 2016 to 2020
$1.8M
NCATS NIH HHS UL1 TR001863NCI NIH HHS R01 CA245313NINDS NIH HHS R01 NS095817
6 · The paper itself

Abstract

backgroundImproved treatment of glioblastoma (GBM) needs to address tumor invasion, a hallmark of the disease that remains poorly understood. In this study, we profiled GBM invasion through integrative analysis of histological and single-cell RNA sequencing (scRNA-seq) data from 10 patients.

methodsHuman histology samples, patient-derived xenograft mouse histology samples, and scRNA-seq data were collected from 10 GBM patients. Tumor invasion was characterized and quantified at the phenotypic level using hematoxylin and eosin and Ki-67 histology stains. Crystallin alpha B (CRYAB) and CD44 were identified as regulators of tumor invasion from scRNA-seq transcriptomic data and validated in vitro, in vivo, and in a mouse GBM resection model.

resultsAt the cellular level, we found that invasive GBM are less dense and proliferative than their non-invasive counterparts. At the molecular level, we identified unique transcriptomic features that significantly contribute to GBM invasion. Specifically, we found that CRYAB significantly contributes to postoperative recurrence and is highly co-expressed with CD44 in invasive GBM samples.

conclusionsCollectively, our analysis identifies differentially expressed features between invasive and nodular GBM, and describes a novel relationship between CRYAB and CD44 that contributes to tumor invasiveness, establishing a cellular and molecular landscape of GBM invasion.

Indexed as

Brain NeoplasmsGlioblastomaGliomaAnimalsCell Line, TumorDisease Models, AnimalGene Expression ProfilingHumansMiceNeoplasm InvasivenessCRYABglioblastomainvasionpostoperative recurrencesingle-cell RNA sequencing

Identifiers

PMID35901838
PMCPMC10013636
OpenAlexW4288536053

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.